Colorectal cancer (CRC) is the second most common cancer in Europe and its incidence is steadily increasing. This trend could be reversed through timely secondary prevention (screening). In the last twenty years, CRC screening programs across Europe have experienced considerable improvements (fecal occult blood testing; transition from opportunistic to population based program settings). The Czech Republic is a typical example of a country with a long history of nationwide CRC screening programs in the face of very high CRC incidence and mortality rates. Each year, approximately 8000 people are diagnosed with CRC and some 4000 die from this malignancy. Twenty years ago, the first pilot studies on CRC screening led to the introduction of the opportunistic Czech National Colorectal Cancer Screening Program in 2000. Originally, this program was based on the guaiac fecal occult blood test (FOBT) offered by general practitioners, followed by colonoscopy in cases of FOBT positivity. The program has continuously evolved, namely with the implementation of immunochemical FOBTs and screening colonoscopy, as well as the involvement of gynecologists. Since the establishment of the Czech CRC Screening Registry in 2006, 2405850 FOBTs have been performed and 104565 preventive colonoscopies recorded within the screening program. The overall program expanded to cover 25.0% of the target population by 2011. However, stagnation in the annual number of performed FOBTs lately has led to switching to the option of a population-based program with personal invitation, which is currently being prepared.

Miroslav Zavoral Stepan Suchanek Premysl Fric Petra Minarikova Department of Medicine 1 Faculty of Medicine Military University Hospital Charles University CZ 169 02 Prague Czech Republic

Zobrazit více v PubMed

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403. PubMed

Bond JH. Fecal occult blood testing for colorectal cancer. Can we afford not to do this. Gastroenterol Clin North Am. 1997;26:57–70. PubMed

Atkin W, Valori R, Kuipers E, Hoff G, Senore C, Segnan N, Jover R, Schmiegel W, Lambert R, Pox C. Colonoscopic surveillance after adenoma removal. In: Segnan N, Patnick J, von Karsa L, editors. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. 1st ed. Luxembourg: Publications Office of the European Union; 2010. pp. 273–297 ISBN 978-92-79-16435-4.

Watson AJ, Collins PD. Colon cancer: a civilization disorder. Dig Dis. 2011;29:222–228. PubMed

Brenner H, Hoffmeister M, Brenner G, Altenhofen L, Haug U. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. Eur J Cancer. 2009;45:2027–2033. PubMed

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–2357. PubMed PMC

Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, Andreoni B, Arrigoni A, Bisanti L, Casella C, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103:1310–1322. PubMed

Atkin W, Kralj-Hans I, Wardle J, Duffy S. Colorectal cancer screening. Randomised trials of flexible sigmoidoscopy. BMJ. 2010;341:c4618. PubMed

Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359:1207–1217. PubMed PMC

Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477. PubMed

Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471. PubMed

Zheng S, Chen K, Liu X, Ma X, Yu H, Chen K, Yao K, Zhou L, Wang L, Qiu P, et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum. 2003;46:51–58. PubMed

Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, Lapalus MG, Ponchon T, Neuhaus H, Philipper M, et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med. 2009;361:264–270. PubMed

Spada C, Hassan C, Munoz-Navas M, Neuhaus H, Deviere J, Fockens P, Coron E, Gay G, Toth E, Riccioni ME, et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest Endosc. 2011;74:581–589.e1. PubMed

Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704–2714. PubMed

Conteduca V, Sansonno D, Russi S, Dammacco F. Precancerous colorectal lesions (Review) Int J Oncol. 2013;43:973–984. PubMed

Deyhle P. [Colonic cancer--diagnosis, check-up, prevention] Internist (Berl) 1979;20:39–43. PubMed

Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101–121. PubMed

Majek O, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, Nennecke A, Eberle A, Brenner H. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer. 2012;106:1875–1880. PubMed PMC

Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, Fric P. Colorectal cancer screening in Europe. World J Gastroenterol. 2009;15:5907–5915. PubMed PMC

Steliarova-Foucher E, O’Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F. European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. Available from: http://eco.iarc.fr. Last accessed on September 24, 2013.

Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O, Verbeek AL, Kiemeney LA. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011;21:573–577. PubMed

Fric P. The use of haemoccult test in the early diagnosis of colorectal cancer - experience from six pilot studies in Czechoslovakia. In: Hardcastle JD, editor. Haemoccult screening for the early detection of colorectal cancer. Stuttgart: Schattauer; 1986. pp. 73–74.

Fric P, Zavoral M, Dvoráková H, Zoubek V, Roth Z. An adapted program of colorectal cancer screening--7 years experience and cost-benefit analysis. Hepatogastroenterology. 1994;41:413–416. PubMed

Seifert B, Zavoral M, Fric P, Bencko V. The role of primary care in colorectal cancer screening: experience from Czech Republic. Neoplasma. 2008;55:74–80. PubMed

Moss S, Ancelle-Park R, Brenner H. Evaluation and interpretation of screening outcomes. In: Segnan N, Patnick J, von Karsa L, editors. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. 1st ed. Luxembourg: Publications Office of the European Union; 2010. pp. 73–74 ISBN 978-92-79-16435-4.

von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013;45:51–59. PubMed PMC

Suchanek S, Majek O, Vojtechova G, Minarikova P, Rotnaglova B, Seifert B, Minarik M, Kozeny P, Dusek L, Zavoral M. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. Eur J Cancer Prev. 2014;23:18–26. PubMed

Dusek L, Muzik J, Kubásek M, Koptikova J, Zaloudik J, Vyzula R. Epidemiology of malignant tumors in the Czech Republic [online]. Masaryk University, Czech Republic, [2005] Available from: http://www.svod.cz Version 7.0 [2007], ISSN 1802-8861. Last accessed on September 12, 2013.

World Health Organization. International statistical classification of diseases and related health problems, 10th revision (ICD-10) Geneva: World Health Organization; 1992. Available from: http://apps.who.int/classifications/icd10/browse/2010/en. Last accessed on September 27, 2013.

Sobin LH, Gospodarowicz MK, Wittekind CH (eds) TNM Classification of Malignant Tumors. 7th ed. Oxford: Willey-Blackwell; 2009.

World Health Organization. WHO Statistical Information System. Geneva, Switzerland: WHO Databank [cit; 2010. p. Sep 4]. Available from: http://www.who.int/whosis/en. Last accessed on September 27, 2013.

Pavlik T, Dusek L, Majek O, Zaloudik J. Five Year Survival Rates of Cancer Patients in the Czech Republic. In: Dusek L, editor. Czech Cancer Care in Numbers 2008-2009. Prague: Grada Publishing; 2009. pp. 339–376.

Kuipers EJ, Rösch T, Bretthauer M. Colorectal cancer screening--optimizing current strategies and new directions. Nat Rev Clin Oncol. 2013;10:130–142. PubMed

Bretthauer M. Colorectal cancer screening. J Intern Med. 2011;270:87–98. PubMed

Benson VS, Atkin WS, Green J, Nadel MR, Patnick J, Smith RA, Villain P. Toward standardizing and reporting colorectal cancer screening indicators on an international level: The International Colorectal Cancer Screening Network. Int J Cancer. 2012;130:2961–2973. PubMed

Rozen P, Blanchard J, Campbell D, Carlsen E, Lambert R, Marbet U, Peterson K, Regula J, Segnan N, Suchanek S, et al. Implementing Colorectal Cancer Screening: Group 2 Report. ESGE/UEGF Colorectal Cancer--Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20 - 22, 2003. Endoscopy. 2004;36:354–358. PubMed

Karsa LV, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, Segnan N, Castillo-Beltran M, Boniol M, Ferlay J, et al. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening - First Report. European Communities (publ. ) Luxembourg: Publication Office of the European Commission; 2008. pp. ISBN 978–92-79-08934-3.

Benson VS, Patnick J, Davies AK, Nadel MR, Smith RA, Atkin WS. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008;122:1357–1367. PubMed

Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371. PubMed

van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90. PubMed

Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, Messersmith H, Lewis N. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012;26:131–147. PubMed PMC

Bowyer HL, Vart G, Kralj-Hans I, Atkin W, Halloran SP, Seaman H, Wardle J, Wagner Cv. Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of colorectal cancer. J Med Screen. 2013;20:149–156. PubMed

Deutekom M, van Rossum LG, van Rijn AF, Laheij RJ, Fockens P, Bossuyt PM, Dekker E, Jansen JB. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective. Scand J Gastroenterol. 2010;45:1345–1349. PubMed

Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150:162–169. PubMed

Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, Kuipers EJ, van Leerdam ME, van Ballegooijen M. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut. 2013;62:727–734. PubMed PMC

Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer. 2001;37:398–401. PubMed

Malila N, Palva T, Malminiemi O, Paimela H, Anttila A, Hakulinen T, Järvinen H, Kotisaari ML, Pikkarainen P, Rautalahti M, et al. Coverage and performance of colorectal cancer screening with the faecal occult blood test in Finland. J Med Screen. 2011;18:18–23. PubMed

Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, Butruk E. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795–1803. PubMed

Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863–1872. PubMed

Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, Regula J, van Leerdam M, Stefansson T, Påhlman L, et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012;44:695–702. PubMed PMC

Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633. PubMed

Robb K, Power E, Kralj-Hans I, Edwards R, Vance M, Atkin W, Wardle J. Flexible sigmoidoscopy screening for colorectal cancer: uptake in a population-based pilot programme. J Med Screen. 2010;17:75–78. PubMed

Sali L, Grazzini G, Ventura L, Falchini M, Borgheresi A, Castiglione G, Grimaldi M, Ianniciello N, Mallardi B, Zappa M, et al. Computed tomographic colonography in subjects with positive faecal occult blood test refusing optical colonoscopy. Dig Liver Dis. 2013;45:285–289. PubMed

Riccioni ME, Urgesi R, Cianci R, Bizzotto A, Spada C, Costamagna G. Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties. World J Gastrointest Endosc. 2012;4:99–107. PubMed PMC

Pox C. Colon cancer screening: which non-invasive filter tests. Dig Dis. 2011;29 Suppl 1:56–59. PubMed

Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–256; quiz e25-6. PubMed PMC

Segnan N, Patnick J, von Karsa L. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. 1st ed. Luxembourg: Publications Office of the European Union; 2010. pp. 1–386.

Denis B, Ruetsch M, Strentz P, Vogel JY, Guth F, Boyaval JM, Pagnon X, Ebelin JF, Gendre I, Perrin P. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut. 2007;56:1579–1584. PubMed PMC

Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–68. PubMed

Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut. 2012;61:1439–1446. PubMed PMC

Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen. 2005;12:28–32. PubMed

Malila N, Oivanen T, Malminiemi O, Hakama M. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ. 2008;337:a2261. PubMed PMC

Peris M, Espinàs JA, Muñoz L, Navarro M, Binefa G, Borràs JM. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain) J Med Screen. 2007;14:81–86. PubMed

Steele RJ, McClements PL, Libby G, Black R, Morton C, Birrell J, Mowat NA, Wilson JA, Kenicer M, Carey FA, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut. 2009;58:530–535. PubMed

UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ. 2004;329:133. PubMed PMC

Weller D, Coleman D, Robertson R, Butler P, Melia J, Campbell C, Parker R, Patnick J, Moss S. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer. 2007;97:1601–1605. PubMed PMC

Kovarova JT, Zavoral M, Zima T, Zak A, Kocna P, Kohout P, Granatova J, Vanickova Z, Vranova J, Suchanek S, et al. Improvements in colorectal cancer screening programmes - quantitative immunochemical faecal occult blood testing - how to set the cut-off for a particular population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156:143–150. PubMed

Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–1687. PubMed

Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013;104:9–14. PubMed PMC

Krämer HU, Müller H, Stegmaier C, Rothenbacher D, Raum E, Brenner H. Type 2 diabetes mellitus and gender-specific risk for colorectal neoplasia. Eur J Epidemiol. 2012;27:341–347. PubMed

Overexpression of CD44v8-10 in Colon Polyps-A Possible Key to Early Diagnosis

Accuracy of Colon Capsule Endoscopy for Colorectal Neoplasia Detection in Individuals Referred for a Screening Colonoscopy

How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?